A Phase I, Open-label, Crossover Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

Recruiting

Phase 1

Laroprovstat & RosuvastatinA Phase I, Open-label, Crossover Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

Sponsor:

AstraZeneca

Code:

NCT07316608

Conditions

Healthy Participants

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Interventions

Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1

Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1

Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2

Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2

Laroprovstat Dose X STP

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-10. This information was provided to ClinicalTrials.gov by AstraZeneca on 2026-04-03.